Restoration of periprosthetic bone loss by zoledronic acid in total hip arthroplasty with osteoporosis.

Restoration of periprosthetic bone loss by zoledronic acid in total hip arthroplasty with osteoporosis. - Restoration of periprosthetic bone loss by zoledronic acid in total hip arthroplasty with osteoporosis.

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000034736

Enrollment

Registered

2019-01-01

Start date

2019-01-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Osteoporotic patients treaed with Total hip arthroplasty

Interventions

zoledronic acid

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: The 123 patitents who were treated with total hip arthroplasety using Versys Fiber Metalwere included in this study and fulfilled the criteia of osteoporosis were included in this study.

Exclusion criteria

Exclusion criteria: The criteria of osteoporosis were not fulfilled.

Design outcomes

Primary

Measure	Time frame
The changes of periprosthetic bone mineral density were compared and evaluated at two years.	—

Secondary

Measure	Time frame
Bone mineral density, bone biomarker, Japanese orthopaedic asssciation hip scpre, WOMAC were compared between groups.	—

Countries

Japan

Contacts

Public ContactWataru Ando

Osaka University Graduate School of Medicine Orthopedic Medical Engineering

w-ando@umin.ac.jp06-6879-3271

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026